Supplementary material.

Table S1. ETM_{30} (mean +/- SD), dosage and carrier (aqueous or oil) for drugs shown in Figure 1A.

Table S2. ETM_{30} (mean +/- SD), dosage and carrier (aqueous or oil) for drugs shown in in Figure 1D.

Table S3. PCR primers for genotyping Oprm1, Abcbla, Pde6b, and Htt R6/2 mice.

Figure S1. Representative examples of eye movement recordings before and after IP injection of phosphate buffered saline. Data are shown

for four mice (labeled A-D). Each mouse was exposed to alternating 30 second intervals of a uniform grey stimulus or to moving black and white vertical stripes, as described for Figure 1A. Eye movements were recorded during the ~15 minutes immediately before and the ~15 minutes immediately after the IP injection. Three representative 90-second segments are shown for each mouse before (upper panels) and after (lower panels) the IP injection. OKR amplitude and timing show some variation from panel to panel, and on average several spontaneous eye movements are seen per 30-second rest period. IP injection of PBS has no effect on the OKR or the frequency of spontaneous eye movements. Scale bar: 0.5 mm.

Figure S2. Kaplan-Meier survival curve for $Abcb1a^{+/+}$ and $Abcb1a^{-/-}$ littermates following a single IP injection of 0.5 mg/kg ivermectin.

| Drug | ETM Average | Standard deviation | Dose | N = Number of Mice | Solvent |
|-------------------|-------------|--------------------|---------------|--------------------|-----------------|
| preinjection | 9.9 | 1.2 | NA | 9 | NA |
| amantadine | 2.4 | 0.8 | 75mg/kg | 3 | aqueous |
| baclofen | 6.6 | 1.6 | 5 and 10mg/kg | 7 | aqueous |
| bromocriptine | 6.6 | 1.4 | 45mg/kg | 4 | oil |
| buspirone | 7.5 | 0.4 | 5mg/kg | 3 | aqueous |
| caffeine | 5.3 | 1.2 | 75mg/kg | 3 | aqueous |
| carbamazepine | 9.1 | 1.1 | 20mg/kg | 3 | oil |
| chloral hydrate | 0.3 | 0.1 | 400mg/kg | 3 | aqueous |
| chlorpromazine | 1.7 | 0.6 | 5mg/kg | 3 | aqueous and oil |
| clobazam | 0.4 | 0.4 | 5mg/kg | 4 | oil |
| clozapine | 0.1 | 0.2 | 12.5mg/kg | 3 | oil |
| clonidine | 1.1 | 0.3 | 75mg/kg | 3 | aqueous |
| desipramine | 4.3 | 0.5 | 25mg/kg | 4 | aqueous |
| fluoxetine | 6.7 | 1.7 | 20mg/kg | 3 | aqueous |
| haloperidol | 0.6 | 0.5 | 10mg/kg | 3 | oil |
| l-dopa | 8.1 | 1.6 | 100mg/kg | 2 | aqueous |
| lithium | 8 | 0.6 | 56mg/kg | 3 | aqueous |
| memantine | 4.7 | 0.5 | 30mg/kg | 3 | aqueous |
| meprobamate | 3.9 | 1.4 | 100mg/kg | 2 | oil |
| methylphenidate | 9.9 | 1.6 | 20mg/kg | 3 | aqueous |
| methysergide | 1.5 | 0.3 | 30mg/kg | 3 | aqueous |
| modafinil | 8.4 | 0.3 | 30mg/kg | 3 | oil |
| mk-801 | 0.7 | 1.2 | 10mg/kg | 3 | aqueous |
| nicotine | 9.5 | 0.6 | 10mg/kg | 3 | aqueous |
| nipecotic acid | 8.3 | 1.8 | 225mg/kg | 3 | aqueous |
| pentylenetetrazol | 0.7 | 0.5 | 50mg/kg | 3 | aqueous |
| perphenazine | 2.4 | 1.8 | 5mg/kg | 3 | oil |
| phenobarbital | 0.6 | 0.2 | 20mg/kg | 2 | aqueous |
| tacrine | 4.2 | 4.3 | 10mg/kg | 4 | aqueous |
| trihexyphenidyl | 14.3 | 1.2 | 40mg/kg | 3 | oil |
| valproic acid | 10.1 | 0.5 | 150mg/kg | 2 | aqueous |
| vigabatrin | 8.4 | 0.6 | 125mg/kg | 3 | aqueous |

Cahill et al. Supplemental Table 1

| Drug | ETM Average | Stand. Deviation | Dose | N=Number of Mice | Solvent |
|---------------|-------------|------------------|---------------|------------------|---------|
| preinjection | 9.9 | 1.2 | NA | 9 | NA |
| amphetamine | 10.7 | 1.7 | 3mg/kg | 3 | aqueous |
| anandamide | 2.7 | 2.8 | 100mg/kg | 2 | oil |
| buprenorphine | 9.1 | 1.9 | 10mg/kg | 6 | aqueous |
| cocaine | 1.1 | 0.6 | 50mg/kg | 4 | aqueous |
| codeine | 7.7 | 0.8 | 20mg/kg | 4 | aqueous |
| ethanol | 5.5 | 1.5 | 1980mg/kg | 4 | aqueous |
| gp1a | 7.5 | 0.6 | 25mg/kg | 3 | oil |
| ketamine | 31.5 | 11.4 | 50mg/kg | 4 | aqueous |
| methadone | 3 | 0.6 | 20mg/kg | 3 | aqueous |
| morphine | 5 | 2 | 30,40,65mg/kg | 5 | aqueous |
| naloxone | 8.9 | 1.8 | 60mg/kg | 4 | aqueous |
| phencyclidine | 20 | 9.6 | 10mg/kg | 6 | aqueous |
| snc-80 | 1.5 | 1.5 | 60mg/kg | 3 | aqueous |

Cahill et al. Supplemental Table 2

| Primer Name | Gene | Allele | Primer Sequence |
|-------------|--------|---------------------|----------------------------|
| HC398 | Abcb1a | wildtype | CTGGGATTTGCCTCAAATCCATTCT |
| HC399 | Abcb1a | wildtype | TCCCCTGCCAGTTGTGAACAAGAAAC |
| HC389 | Abcb1a | knockout | ATGTCCTGCGGGTAAATAGC |
| HC390 | Abcb1a | knockout | CGTCAGGACATTGTTGGAGC |
| HC362 | Oprm1 | knockout | GCCAGAGGCCACTTGTGTAG |
| HC363 | Oprm1 | wildtype & knockout | ATCTTCACCCTCTGCACCAT |
| HC364 | Oprm1 | wildtype | TGCTGGGCTCCAGCTTTAAT |
| HC405 | Htt | R6/2 transgene | ACGCAAGGCGCCGTGGGGGGCTGCCG |
| HC406 | Htt | R6/2 transgene | CGACTCGCGGCGCCGCTCAGCACCG |
| HC86 | Pde6b | rd1 | CATCCCACCTGAGCTCACAGAAAG |
| HC87 | Pde6b | rd1 | GCCTACAACAGAGGAGCTTCTAGC |

Cahill et al. Supplemental Table 3 Eye Position

Post PBS injection

Pre - injection



Cahill et al Figure S1



Cahill et al Figure S2